Media headlines about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have been trending somewhat positive on Tuesday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.3439623191982 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) opened at $4.08 on Tuesday. Brainstorm Cell Therapeutics has a 52-week low of $2.06 and a 52-week high of $5.18.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. During the same quarter in the previous year, the firm posted ($0.09) EPS. analysts forecast that Brainstorm Cell Therapeutics will post -0.37 earnings per share for the current year.
Several research firms recently commented on BCLI. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 16th. ValuEngine raised shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.